Precigen’s immunotherapy will likely reduce the need for repeat surgeries in recurrent respiratory papillomatosis (RRP) ...

Germantown: Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

US FDA approves Precigen’s Papzimeos for the treatment of adults with recurrent respiratory papillomatosis: Germantown, Maryland Monday, August 18, 2025, 17:00 Hrs [IST] Precige ...

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ...

The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults ...

Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

Today marks my last Care and Feeding column. Nearly three and a half years ago, I dared to get back into journalism and ...

Precigen (PGEN) stock jumps as the FDA approves the company's gene therapy Papzimeos for adults with recurrent respiratory ...

The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis (RRP). Papzimeos is a non-replicating adenoviral ...